RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MAURO F
Collezione AO Cuneo

Items : 6

SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. in Hematological oncology / Hematol Oncol. 2023 Feb;41(1):128-138. doi: 10.1002/hon.3092. Epub 2022 Oct 25.

2023
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Visco C; Corradini P; Passamonti F; Bertù L; Guidetti A; Gherlinzoni F; Pagano L; Visani G; Federici AB; Tisi MC; Cudillo L; Galimberti S; Cilloni D; Della Porta MG; Coviello E; Mohamed S; Mauro FR; Gentile M; Gambacorti-Passerini C; Bocchia M; Massaia M; Billio A; Fracchiolla NS; Marchesi F; Scattolin A; Trentin L; Cattaneo C; Derenzini E; Cavo M; et alii...

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino

Fazi P; Vignetti M; Guarini A; Cuneo A; Piciocchi A; De Propris MS; Nanni M; Del Giudice I; Neri A; De Novi LA; Albano F; Vitale C; Visentin A; Pietrasanta D; Mattiello V; Molinari MC; Liberati AM; Giordano A; Patrizi VB; Gottardi D; Galieni P; Deodato M; Arcari A; Musuraca G; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...

How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. in Leukemia & lymphoma / Leuk Lymphoma. 2022 Aug;63(8):1985-1988. doi: 10.1080/10428194.2022.2053532. Epub 2022 Mar 27.

2022
AO Cuneo
AOU Città della Salute di Torino

Tedeschi A; Montillo M; Zamprogna G; Marinoni S; Ferrario A; Tani M; Varettoni M; Borella C; Ferrarini I; Sanna A; Motta M; Ibatici A; Orsucci L; Massaia M; Vitale C; Vanazzi A; Mauro FR; Quaresmini G; Visentin A; Reda G; Murru R; Laurenti L; Sportoletti P; Frustaci AM; Deodato M;

Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. in Hematological oncology / Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.

2021
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino

Pietrasanta D; Foà R; Chiarenza A; Penna G; Orsucci L; Levato L; Gentile M; Sanna A; Gozzetti A; Gattei V; Gottardi D; Derenzini E; Murru R; Leone M; Baratè C; Olivieri J; Tisi MC; Stefoni V; Malerba L; Ibatici A; Del Poeta G; Varettoni M; Chiurazzi F; Marasca R; Farina L; Re F; De Paoli L; Foglietta M; Giordano A; et alii...

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Apr;105(4):1042-1054. doi: 10.3324/haematol.2019.217430. Epub 2019 Jul 9.

2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino

Coscia M; Foà R; Massaia M; Gaidano G; Bernardi R; Gattei V; Zenz T; Mauro FR; Del Poeta G; Laurenti L; Omedè P; Kodipad AA; Marchetti M; Bonello L; Magliulo D; Bo MD; Pozzato G; Rossi D; Bomben R; Riganti C; Salvetti C; Kopecka J; Todaro M; Vitale C; Griggio V; Boccadoro M;

Effects of a short-term alirocumab administration on the aortic stiffness: preliminary results. in Journal of geriatric cardiology : JGC / J Geriatr Cardiol. 2019 Oct;16(10):782-784. doi: 10.11909/j.issn.1671-5411.2019.10.001.

2019
AO Cuneo
ASL Cuneo 1

Tassone F; Marzia T; Gaetano R; Arianna R; Cinzia F; Mauro F;